eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2015
vol. 19
 
Share:
Share:
abstract:
Original paper

Genistein-induced mir-23b expression inhibits the growth of breast cancer cells

Cigir Biray Avci
,
Sunde Yilmaz Susluer
,
Hasan Onur Caglar
,
Tugce Balci
,
Duygu Aygunes
,
Yavuz Dodurga
,
Cumhur Gunduz

Contemp Oncol (Pozn) 2015; 19 (1): 32–35
Online publish date: 2014/08/26
View full text Get citation
 
PlumX metrics:
Aim of the study: Genistein, an isoflavonoid, plays roles in the inhibition of protein tyrosine kinase phosphorylation, induction of apoptosis, and cell differentiation in breast cancer. This study aims to induce cellular stress by exposing genistein to determine alterations of miRNA expression profiles in MCF-7 cells.

Material and methods: XTT assay and trypan blue dye exclusion assays were performed to examine the cytotoxic effects of genistein treatment. Expressions of miRNAs were quantified using Real-Time Online RT-PCR.

Results: The IC50 dose of genistein was 175 μM in MCF-7 cell, line and the cytotoxic effect of genistein was detected after 48 hours. miR-23b was found to be up-regulated 56.69 fold following the treatment of genistein. It was found that miR-23b was up-regulated for MCF-7 breast cancer cells after genistein treatment.

Conclusions: Up-regulated ex-expres-sion of miR-23b might be a putative biomarker for use in the therapy of breast cancer patients. miR-23b up-regulation might be important in terms of response to genistein.
keywords:

breast cancer, genistein, miRNA, MCF-7

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.